$-0.34 EPS Expected for Crinetics Pharmaceuticals, Inc. (CRNX)

November 11, 2018 - By Peter Erickson

Analysts expect Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) to report $-0.34 EPS on November, 29.After having $-2.41 EPS previously, Crinetics Pharmaceuticals, Inc.’s analysts see -85.89 % EPS growth. The stock decreased 4.69% or $1.32 during the last trading session, reaching $26.84. About 41,610 shares traded. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) has 0.00% since November 11, 2017 and is . It has underperformed by 15.62% the S&P500.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. The company has market cap of $644.81 million. The Company’s lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. It currently has negative earnings. The firm is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>